Barrington James’ Post

Our Ophthalmology capabilites and expertise are second to none. if you have a spare minute, watch the below. AC #syneos #opthalmology

Breaking barriers in glaucoma treatment! Celanese Corporation and Glaukos Corporation join forces to introduce iDose(R) TR, a game-changer in sustained drug release for better patient outcomes. Discover how this innovative solution is reshaping ophthalmology! #GlaucomaInnovation #CelaneseImpact #MedicalAdvancements #EyeCare #TidbitThursday

New article published in which the VISIONR&D CELab has played a key role in the development of the study 🙌 👉Short-Term Efficacy of Ophthalmic Cyclosporine: A 0.1% Cationic Emulsion in Dry Eye Patients Assessed Under Controlled Environment. Published in Ophthalmology and Therapy.  Topical CsA-0.1% CE improved DED signs and symptoms after 1 month of treatment under controlled environmental conditions. Future studies should confirm the benefit of CsA-0.1% CE in desiccating stress environments. Read the full article for more insights. 🌐https://lnkd.in/d8i3SkA9 #VisionRD #OphthalmicResearch #DryEye #Innovation #CELab

What do the best ophthalmology sponsors do differently that make a tangible difference to the execution of a clinical trial? According to our team, it's these 5 specific things 👇 _____________________ #ophthalmology #clinicaltrials #lifesciences

Explore this insightful discussion featuring our recently appointed CEO, Jeanne Hecht! With a wealth of experience in the industry, she shares valuable insights into trends in ophthalmology clinical trials and offers advice for sponsors embarking on their own ophthalmic studies. Don't miss out on this engaging conversation!

Reminder! You still have time to sign up for our webinar on "Addressing Ophthalmology Clinical Trial Design and Effective Data Monitoring Committee Strategies" happening at 1:30pm CEST (EU-Central). Don't miss out! Register here: https://hubs.la/Q02h5Bv50 #Ophthalmology #Biostatistics #ClinicalTrials #CROpartner #DataMonitoringCommittees

Come visit us at Booth #125 at the American Academy of Ophthalmology Annual Meeting! We are looking forward to learning about the latest innovations in #wetAMD and sharing insights from recent studies establishing clinical equivalence between our #biosimilar and Lucentis. Check out this video: bit.ly/3QLSiuo

Check out our latest short video featuring Priya Vakharia as she discusses key insights and advancements in ophthalmology in partnership with Lexitas Pharma. In just under a minute, you'll gain valuable knowledge about our commitment to excellence in clinical trials and patient care. Watch now to learn more about how Lexitas Pharma is leading the way in ophthalmic research and innovation! 🌟 https://lnkd.in/gNn9y39f #LexitasPharma #Ophthalmology #ClinicalTrials #Innovation #Healthcare #MedicalResearch #PatientCare #DrVakharia

The disparities in healthcare systems can significantly influence patient care. In Japan, it's typical for patients to bear co-payments ranging from 10-30%. The differences extend further—programs common in the US are often deemed unfeasible within Japan's healthcare framework.